Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 9/20 | 0.71 |
| ▸ | HTR2A | P28223 | 4/20 | 0.67 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HTR3A | P46098 | 1/20 | 0.56 |
| ▸ | BACE1 | P56817 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5154236 | 0.97 | TAAR1 (0.68) | TAAR1HTR2ACYP2A6CYP1A2KDM4E | |
| SCHEMBL26189798 | 0.87 | TAAR1 (0.61) | TAAR1HTR2ACYP2A6CYP1A2ALDH1A1 | |
| SCHEMBL224548 | 0.85 | TAAR1 (0.72) | TAAR1HTR2ACYP2A6CYP1A2KDM4E | |
| SCHEMBL142480 | 0.85 | LPL (0.62) | TAAR1HTR2AKDM4EALDH1A1ADRA2A | |
| SCHEMBL6279898 | 0.84 | HTR2A (0.61) | TAAR1HTR2ACYP2A6CYP1A2KDM4E | |
| SCHEMBL3062920 | 0.84 | HTR2A (0.83) | TAAR1HTR2ACYP2A6CYP1A2KDM4E | |
| Ethylamine SCHEMBL27859952 | 0.84 | GFER (0.62) | TAAR1HTR2ACYP2A6CYP1A2ALDH1A1 | |
| SCHEMBL5962 | 0.83 | GFER (0.68) | TAAR1HTR2AALDH1A1LOXL2TDP1 | |
| SCHEMBL396116 | 0.83 | HRH3 (0.52) | TAAR1HTR2ACYP2A6CYP1A2LOXL2 | |
| SCHEMBL4920 | 0.83 | TAAR1 (1.00) | TAAR1HTR2ACYP2A6CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275236-A1 | DIAMINE COMPOUNDS, DINITRO COMPOUNDS AND OTHER COMPOUNDS, AND METHODS OF PRODUCING THEREOF AND USES RELATED THEREOF | MICROMIDAS, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-8394979-B2 | Process for preparing cycloplatinated platinum complexes, platinum complexes prepared by this process and the use thereof | RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) | 2013-03-12 | — | — | US | disclosed |
| US-20100267977-A1 | METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF | RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20090104119-A1 | Dendrimer Based Compositions And Methods Of Using The Same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-23 | — | — | US | disclosed |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090088376-A1 | DENDRIMER BASED COMPOSITIONS AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090053139-A1 | Dendrimer based compositions and methods of using the same | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-02-26 | — | — | US | disclosed |
| EP-1131290-B1 | PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-02-20 | — | — | EP | disclosed |
| US-20070041934-A1 | Dendrimer based compositions and methods of using the same | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-02-22 | — | — | US | disclosed |
| CN-1267501-C | Light sensitivity resin precursor compsn. | TORAY INDUSTRIES (JP) | 2006-08-02 | — | — | CN | disclosed |
| US-6770650-B2 | CHEMOKINE RECEPTOR (CCR) ANTAGONISTS SUCH AS N-(1(S)-(4-(3,4-DICHLOROBENZYL)PIPERAZIN-1-YLMETHYL)-2-METHYLPROPYL)-4 -METHYLBENZAMIDE DIHYDROCHLORIDE SALT FOR TREATMENT OF ASTHMA | SYNTEX (U.S.A.) LLC | 2004-08-03 | — | — | US | disclosed |
| CN-1154708-C | Chemical-ray sensitive polymer composition | 东丽株式会社 | 2004-06-23 | — | — | CN | disclosed |
| CN-1480491-A | Light sensitivity resin precursor compsn. | ������������ʽ���� | 2004-03-10 | — | — | CN | disclosed |
| US-6323223-B1 | CCR-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, METHODS FOR THEIR USE AND METHODS FOR PREPARING THESE COMPOUNDS. | SYNTEX (U.S.A.) LLC | 2001-11-27 | — | — | US | disclosed |
| CN-1201061-A | Chemical-ray sensitive polymer composition | TORAY CO LTD (JP) | 1998-12-09 | — | — | CN | disclosed |
| US-4948809-A | TREATMENT OF AILMENTS DUE TO THROMBOCYTE AGGREGATION OR KIDNEY DYSFUNCTION | BOEHRINGER MANNHEIM GMBH (DE) | 1990-08-14 | — | — | US | disclosed |
| EP-0221344-B1 | SULPHONYL-PHENYL ALKYL AMINES, PROCESS FOR THEIR PREPARATION AND MEDICINES | Roche Diagnostics GmbH (DE) | 1990-05-23 | — | — | EP | disclosed |
| EP-0221344-A1 | Sulphonyl-phenyl alkyl amines, process for their preparation and medicines | Roche Diagnostics GmbH (DE) | 1987-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275236-A1 | DIAMINE COMPOUNDS, DINITRO COMPOUNDS AND OTHER COMPOUNDS, AND METHODS OF PRODUCING THEREOF AND USES RELATED THEREOF | DDC, DDT, DAO | TAAR1 833/4885HTR2A 1665/4885CYP2A6 1637/4885 |
| US-20090104119-A1 | Dendrimer Based Compositions And Methods Of Using The Same | TLR9, CD63, CD47 | TAAR1 1743/4885HTR2A 4606/4885CYP2A6 4862/4885 |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | ALDH1A2, PDE6C, EYA2 | TAAR1 3952/4885HTR2A 3014/4885CYP2A6 4363/4885 |
| US-20100267977-A1 | METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF | THPO, MCL1, PPOX | TAAR1 4519/4885HTR2A 4718/4885CYP2A6 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.